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Background: Dovitinib is a receptor tyrosine kinase (RTK) inhibitor targeting vascular endothelial growth factor
receptors, fibroblast growth factor receptors and platelet-derived growth factor receptor β. Dovitinib is currently in
clinical trials for the treatment of hepatocellular carcinoma (HCC).
Method: In this study, we used five HCC cell lines and five endothelial cell lines to validate molecular and cellular
targets of dovitinib.
Results: Tumor growth and pulmonary metastasis were significantly suppressed in an orthotopic HCC model.
Immunoblotting revealed that among known dovitinib targets, only PDGFR-β was expressed in two HCC cell lines,
while four of five endothelial lines expressed PDGFR-β, FGFR-1, and VEGFR-2. Dovitinib inhibited endothelial cell
proliferation and motility at 0.04 μmol/L, a pharmacologically relevant concentration; it was unable to inhibit the
proliferation or motility of HCC cells at the same concentration. Immunohistochemical analyses showed that
dovitinib significantly decreased the microvessel density of xenograft tumors, inhibiting proliferation and inducing
apoptosis in HCC cells.
Conclusion: Our findings indicate that dovitinib inhibits HCC growth and metastasis preferentially through an
antiangiogenic mechanism, not through direct targeting of HCC cells.
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Hepatocellular carcinoma (HCC) is characterized by
highly vascularized and rapid tumor progression, a high
recurrence rate after surgical resection, and an extremely
poor prognosis. It is the fifth most common cancer in
the world, and the third most frequent cause of cancer
death [1-4]. The highly vascularized nature of HCC has
been considered as the main reason for its devastating
outcome, because of intrahepatic and distant metastases
[5-7]. Vascular endothelial growth factor (VEGF), basic
fibroblast growth factor (bFGF), and platelet-derived* Correspondence: qianchn@sysucc.org.cn; guorp@sysucc.org.cn
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reproduction in any medium, provided the orgrowth factor (PDGF) are three important pro-
angiogenic factors involved in hepatocarcinogenesis, and
they participate in the neovascular, invasive, and meta-
static potentials of HCC [8-11].
VEGF expression is detected in dysplastic nodules and
correlates with histological grades; VEGF is increased
during hepatocarcinogenesis [8]. Sorafenib, an inhibitor
of several kinases, including Raf-1 and VEGF receptor
(VEGFR), is currently the first-line therapy for advanced
or recurrent HCC. It has a modest survival benefit, but
patients develop subsequent drug resistance [12-14].
Dovitinib (TKI258; formerly CHIR258) is a potent in-
hibitor of receptor tyrosine kinases (RTKs). It inhibits
VEGFR-1, VEGFR-2, and VEGFR-3; fibroblast growth
factor receptors (FGFR1, FGFR2, and FGFR3); and
platelet-derived growth factor receptor β (PDGFR-β)
[15,16]. Dovitinib is reported to directly inhibit the pro-
liferation and survival of colon cancer and leukemiatd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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locations in the target RTKs or their ligands, at pharma-
cologically relevant concentrations of 0.01–0.3 μmol/L
[17-19].
In preclinical studies, dovitinib has been able to inhibit
xenograft HCC growth in immunodeficient mice and
even overcome sorafenib resistance [20,21]. However,
the lack of somatic mutations of RTK genes in HCC has
caused doubt about whether HCC cells are the primary
cellular target of dovitinib [22]. It has been reported that
endothelial cells and perivascular cells (pericytes) can ex-
press VEGFR, PDGFR, and/or FGFR [8,23,24]; thus,
these cells are theoretical targets of dovitinib, and the
drug might act as an angiogenesis inhibitor in vivo.
However, the ability of dovitinib to suppress tumor
angiogenesis has not been established.
In the present study, our aim was to reveal the cellular
targets of dovitinib in HCC treatment at pharmacologic-
ally relevant concentrations, which is crucial for the fu-
ture development of this treatment strategy.
Materials and methods
Kinase inhibitor
Dovitinib (CHIR-258, TKI258) [4-amino-5-fluoro-3-[6
(4-methyl-1-piperazinyl)-1H- benzimidazol-2-yl]-2(1H)-
quinolinone], with a molecular weight of 392.4, was
provided by Novartis Pharma AG (Novartis Institutes
for Biomedical Research, Basel, Switzerland).
Cells and cell culture
The human HCC cell lines MHCC-97H, QGY-7703,
SMMC7721, Hep3B, and CRI2234, as well as a human
bone marrow endothelial (HBME) line, were maintained
in DMEM or RPMI 1640 (Invitrogen) supplemented with
10% fetal bovine serum (FBS; Invitrogen), 100 IU/mL
penicillin, and 100 μg/mL streptomycin (Invitrogen) in
a humidified incubator containing 5% CO2 at 37°C.
Human umbilical vascular endothelial cells (HUVECs),
human dermal microvascular endothelial cells (HMVECs),
human umbilical artery endothelial cells (HUAECs), and
human lung microvascular endothelial cells (HLMVECs)
were maintained in Clonetics Endothelial Basal Medium-2
(EBM-2) supplemented with essential growth factor sup-
plements EGM-2 SingleQuots or EGM-MV SingleQuots
(Lonza). All the cell lines were used within 50 passages.Cell viability assay
Cell viability was assessed using an 3-(4,5-dimethylthiazol-
2-yl)-5-(3- carboxymethoxyphenyl) -2- (4-sulfophenyl)-
2H-tetrazolium (MTS) assay kit (Sigma) with dye conver-
sion at 490 nm, following the manufacturer’s instructions.
Briefly, cells were seeded 3 × 103/well in a 96-well flat-
bottomed plate and starved in no serum for 18 h, andwere then treated with increasing concentrations of doviti-
nib and stimulated with 30 ng/mL recombinant human
VEGF or PDGF-BB (Sigma V7259 or SRP3138). At 72 h,
20 μl of MTS was added to each well. After 1.5 h of incu-
bation at 37°C, the results were analyzed by a plate reader
at 490 nm. The sample data was normalized to back-
ground readings of medium only.
In vitro migration and invasion assays
For Transwell migration assays, 5.0 × 104 HCC cells or
endothelial cells in 500 μl of serum-free DMEM or EBM
were added to the cell culture inserts with an 8-μm
microporous filter without an extracellular matrix coat-
ing (Becton Dickinson Labware). To the bottom cham-
ber was added 800 μL of DMEM or EGM containing
10% FBS. After 24 h of incubation, the cells on the lower
surface of the filter were fixed, stained, and counted
under a microscope (×100 magnification). The number
of migrated cells in five random optical fields from tripli-
cate filters was averaged. For invasion assays, the inserts
of the chambers to which the cells were seeded were
coated with Matrigel (Becton Dickinson Labware). The
number of invaded cells in five random optical fields
(×100 magnification) was averaged from triplicate
inserts.
For the wound healing assay, the cells were plated in
6-well plates (3 × 105 cells/well) and allowed to attach
and reach confluence. A scratch was made using a sterile
100-μl pipette tip and detached cells were removed by
washing with PBS. Phase contrast images were taken at
specified time points. The scratched wound was evalu-
ated at 18 h (endothelial cells) or at 48 h (HCC cells)
after scratching.
Efficacy of dovitinib in an orthotopic HCC model
Male athymic mice between 4 and 5 weeks of age were
purchased from Shanghai Institutes for Biological
Sciences (Shanghai, China). All the animal studies were
conducted in accordance with the principles and proce-
dures outlined in the guidelines of the Institutional Ani-
mal Care and Use Committee at Sun Yat-sen University
Cancer Center. Mice were anesthetized by continuous
inhalation of isoflurane (Baxter Healthcare, NJ).
For orthotopic xenografts, an upper abdominal mid-
line incision was made. MHCC-97H, SMMC7721 or
QGY-7703 HCC cells (1 × 106) in 30 μl of culture
medium with 33% Matrigel were injected into the left
lobe of the liver using an insulin syringe with a 31-gauge
needle (Becton Dickinson, NJ). Two weeks later, the
nude mice were randomized into three groups of 20
mice each and were treated either with 0.9% sodium
chloride or 25 or 50 mg/kg of TKI258 for 14 days. On
day 30 after tumor cell inoculation, the animals were
weighed, euthanized, and autopsied. The liver and lungs
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examine lung metastases, 100 sequential lung sections
(4 μm) were cut from the lungs of each mouse and every
tenth section was stained with hematoxylin and eosin
(H&E).
Immunohistochemistry (IHC)
Formalin-fixed and paraffin-embedded sections 4 μm thick
were dewaxed in xylene and a gradient of alcohols,
hydrated, and washed in PBS. After pretreatment in a
microwave oven (30 min in citrate buffer, pH 6.0), endogen-
ous peroxidase activity was blocked by 0.3% hydrogen per-
oxide for 10 min, and the sections were incubated with
10% normal goat serum for 15 min. Primary antibodies—
rabbit polyclonal anti-CD34 (Santa Cruz Biotechnology,






















































































Figure 1 Dovitinib inhibited the growth and metastasis of HCC in an
tumors was dose-dependently inhibited by dovitinib. The wet liver weight
respectively. The four largest liver tumors of each group are shown. B) Sign
liver weight of 0, 25 and 50 mg/kg were 1.87 ± 0.45, 1.63 ± 0.26 and 1.56 ±
xenograft tumors by dovitinib. The wet liver weight of 0, 25 and 50 mg/kg
mice bearing the high-metastasis HCC cell line MHCC-97H, dose-dependen
microscope. The arrow points to macro-metastasis; scale bar, 100 μm. The
deviation. black star, P < 0.05; double black star, P < 0.01.Cambridge, UK) and rabbit polyclonal anti-PARP (Abcam,
Cambridge, UK)—were applied overnight in a moist cham-
ber at 4°C. A standard avidin-biotin peroxidase technique
(DAKO, Carpinteria, CA) was applied. Briefly, biotinylated
goat anti-rabbit immunoglobulin, goat anti-rat immuno-
globulin, and avidin-biotin peroxidase complex were ap-
plied for 30 min each, with 15-min washes in PBS. The
reaction was finally developed using the DAKO Liquid
DAB+ Substrate-Chromogen System. The methods for
quantification of microvessel density (MVD), proliferation
index, and apoptosis index were reported previously
[25,26]. Briefly, the largest section of each xenograft tumor
was analyzed by randomly capturing images of microscopic
fields at low magnification, and the microvessels or stained
cells were counted and averaged. The final results were the


























































orthotopic xenograft model. A) Growth of MHCC-97H xenograft
of 0, 25 and 50 mg/kg were 2.00 ± 0.54, 1.68 ± 0.31 and 1.41 ± 0.27 g,
ificant inhibition of SMMC7721 xenograft tumors by dovitinib. The wet
0.22 g, respectively. C) Dose-dependent inhibition of QGY-7703
were 3.44 ± 0.72, 2.59 ± 0.45 and 1.91 ± 0.39 g, respectively. D) For the
t inhibition of lung metastases by dovitinib was observed under a
results in panels A-C are expressed as the mean ± the standard
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Cells were lysed in cold RIPA buffer (100 mM Tris HCl,
300 mM NaCl, 2% NP40, 0.5% sodium deoxycholate)
supplemented with a proteinase inhibitor cocktail
(Roche, Indianapolis, IN) and a phosphatase inhibitor
cocktail (Merck, Darmstadt, Germany). Protein concen-
tration was determined using a detergent-compatible
protein assay according to the manufacturer’s instruc-
tions (Bio-Rad). Protein (1 mg) from each sample was
immunoprecipitated overnight at 4°C with an anti-
VEGFR-2, anti-PDGFR-β, or anti-FGFR-1 (Cell Signaling
Technology) antibody plus protein G/A agarose beads
(Pierce). Immune complexes were washed with cold RIPA
buffer containing proteinase inhibitors and phosphatase
inhibitor. Proteins were eluted by boiling in SDS sample
buffer, separated by SDS-PAGE, and transferred to polyvi-
nylidene difluoride membrane (Millipore). Membranes
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Figure 2 Expression profile of RTKs and the effect of dovitinib on RTK
FGFR-1, and VEGFR-2 in HCC and endothelial cell lines as detected by imm
endothelial cell lines C) Phosphorylation of p-PDGFR-β and p-ERK were inh
MHCC-97H and SMMC7721 cells. D) Dovitinib inhibited the phosphorylatio
endothelial cells at pharmacologically relevant concentrations.Signaling Technology) and then stripped with stripping
buffer (Abcam). To detect total VEGFR-2, PDGFR-β, and
FGFR-1 levels, membranes were re-probed with the same
anti-VEGFR-2, anti-PDGFR-β, and anti-FGFR-1 antibody
that was used for the immunoprecipitation. Immunoblot-
ting of phospho- ERK1/2 and ERK1/2 (Cell Signaling
Technology) was performed on whole-cell lysates (40 μg)
with β-actin (Abcam) as a loading control.Statistical analysis
Continuous data were expressed as median and range
and were compared between groups using one-way
ANOVA and Dunnett t test. Categorical variables were
compared using the chi-square test, or Fisher’s exact
test, where appropriate. All data were analyzed using the
SPSS 13.0 computer program, and significant difference
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signaling in HCC and endothelial cells. A) Expression of PDGFR-β,
unoblotting. B) Expression of FGFR-3, and VEGFR-1 in HCC and
ibited by dovitinib at pharmacologically relevant concentrations in
n of FGFG-1, VEGFR-2, and downstream ERK in HMVEC and HUVEC
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Dovitinib inhibited HCC xenograft tumor growth and
metastasis
The therapeutic effect of dovitinib was examined using
the orthotopic HCC model. Continuous dovitinib treat-
ment for 2 weeks at doses of 25 or 50 mg/kg was started
14 days after orthotopic injection of MHCC-97H,
SMMC7721, or QGY-7703 cells. There was no signifi-
cant change in body weight of the animals in each treat-
ment group compared with that of the control animals
(data not shown). Dovitinib significantly inhibited pri-
mary tumor growth in a dose-dependent manner relative
to the control group (Figure 1A–C). In MHCC-97H, a
HCC cell line with high metastasis capability [27], doviti-
nib also inhibited pulmonary metastasis in a dose-
dependent manner (Figure 1D).
Dovitinib inhibited RTK signaling pathways in vitro
Pharmacokinetic and pharmacodynamic studies have
revealed that the pharmacologically relevant concentra-
tion of dovitinib is 0.01–0.3 μmol/L [17,18]. To evalu-
ate the potential effect of dovitinib at pharmacological
concentration on the activation of RTK signaling path-
ways in vitro, we first examined the expression and ac-
tivation of VEGFR, FGFR, PDGFR, Flt-3, and c-KIT in
HCC cell lines and endothelial cell lines by immuno-
blotting. FGFR-3 was expressed by Hep3B and MHCC-
97H, VEGFR-1 was expressed by two endothelial cells
(Figure 2B), PDGFR-β was clearly expressed by two cell




Figure 3 Dovitinib inhibited the proliferation of endothelial cells at p
proliferation of endothelial cells under VEGF, PDGF-BB dependent or norma
B) Proliferation of MHCC-97H and SMMC7721 HCC cells was inhibited onlythe five endothelial cell lines homogenously expressed
VEGFR-2 and FGFR-1 (Figure 2A). Flt-3 and c-KIT
were undetectable in all cell lines (Additional file 1:
Figure S1).
Based on the combined data of the mice and the cell
lines, we focused our study on VEGFR-2, FGFR-1 AND
PDGFR-β signaling in the cells. As expected, dose-
dependence was found in the inhibitory effects of doviti-
nib on the phosphorylation of PDGFR-β, VEGFR-2, and
FGFR-1, as well as their major downstream effector, the
phosphorylation of ERK, on these cells (Figure 2C–D),
but not the phosphorylation of Akt (Additional file 2:
Figure S2B). While the levels of cleaved PARP and
cleaved caspase 3 were also readily detected in dose-
dependence of dovitinib (Additional file 2: Figure S2A).
The proliferation of endothelial cells (but not the HCC
cells) was inhibited by dovitinib
Only two HCC cell lines, MHCC-97H and SMMC7721,
expressed PDGFR-β. Therefore, we compared the inhibi-
tory effect of dovitinib on proliferation in these two lines
and in endothelial cell lines. The IC50 for dovitinib to
inhibit the proliferation of HCC cell lines was 0.87 ±
0.17 μmol/L and 1.26 ± 0.15 μmol/L for MHCC-97H
and SMMC7721, respectively. While dovitinib showed
robust inhibitory effect of endothelial cells under VEGF-
dependent conditions were ~0.04 μmol/L, which was
similar to the concentrations required to inhibit activa-
tion of VEGFR-2 (Figure 3). The IC50 values of MHCC-
97H and SMMC7721 cells were much higher than thatSMMC7721
HMVEC
harmacologically relevant concentration. A) Dovitinib inhibited the
l conditions by MTS assay; results were normalized to DMSO controls.
at high concentrations of dovitinib.
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that targeting of PDGFR-β by dovitinib did not influence
the proliferation of these cells.
Dovitinib inhibited the migration of endothelial cells but
not of HCC cells
Figure 4 shows that at pharmacologically relevant con-
centrations, dovitinib inhibited the migration and inva-
sion of endothelial cells as evaluated by Transwell assay
and wound-healing assay. The motility of MHCC-97H,
SMMC7721 and QGY7703 was very weak in the wound-
healing assay, and dovitinib did not show an significantly
inhibitory effect on their migration of MHCC-97H.
Dovitinib inhibited tumor angiogenesis in vivo
To further elucidate the mechanism of dovitinib-








































Figure 4 Dovitinib inhibited the migration and invasion of endothelia
evaluated by Transwell assay, dovitinib significantly inhibited the migration
B) The migration and invasion of MHCC-97H cells was not inhibited by dov
dovitinib on the migration of endothelial and HCC cells. Consistent with th
inhibited, while MHCC-97H cells did not show motility. Black star, P < 0.01 rcollected xenograft tumor samples and examined the ef-
fect of dovitinib on the tumor vasculature as well as on
HCC cell proliferation and apoptosis. Immunohisto-
chemical analyses revealed that the markers of endothe-
lial cell and pericyte expressed homogeneously in tumor
sample (Additional file 3: Figure S3), and dovitinib sig-
nificantly decreased microvessel density in MHCC-97H
cells by 61.5% and 78.8% at doses of 25 mg/kg and
50 mg/kg, respectively; MVD was decreased by 58.3%
and 74.8%, respectively, in SMMC7721 cells and by
57.9% and 82.6% in QGY-7703 cells (Figure 5). In com-
parison with the robust inhibition of angiogenesis, the
effects of dovitinib on inhibiting proliferation and
enhancing apoptosis of HCC cells in vivo were modest,
although significant (Figure 6), suggesting that direct tar-
geting HCC cells by dovitinib might not be the primary








































l cells at pharmacologically relevant concentrations. A) As
and invasion of HUVEC endothelial cells in a dose-dependent manner.
itinib. C) Wound healing assays showed the inhibitory effect of
e results in the Transwell assay, the migration of HUVEC cells was


















































Figure 5 Dovitinib inhibited tumor angiogenesis in vivo. A) Treatment with dovitinib decreased microvessel density in a dose-dependent
manner. Black star, P < 0.01 relative to the control group. B) Immunohistochemical staining of CD34 showing microvessels in xenograft tumors.
Scale bars, 100 μm.
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Dovitinib is currently in Phase II studies for the
treatment of advanced hepatocellular carcinoma
(NCT01232296), but the underlying mechanism of
dovitinib in targeting HCC is not known. Our results
showed that dovitinib preferentially targeted endothelial
cells by inhibiting their proliferation and motility and inhi-
biting angiogenesis in vivo. At pharmacologically relevant
concentrations, dovitinib did not affect HCC cells.
Other groups have reported that dovitinib concentra-
tions lower than 1 μmol/L are sufficient to inhibit RTK
signaling [17,18]. In cellular assays, Andrew and collea-
gues found that dovitinib inhibited FGFR signaling in
Ba/Fs cells lines of myeloproliferative syndrome with
IC50 values of 0.09–0.15 μmol/L [28], consistent with
our studies on endothelial cells. Finally, both clinical and
preclinical pharmacodynamic studies showed that
pharmacologically and clinically relevant plasma concen-
trations of dovitinib are 0.01–0.3 μmol/L [17,18].
A recent study using a high concentration (1.727 μM)
of dovitinib reported that anchorage-independentgrowth and FGF-induced motility of HCC cells was
inhibited [29]. Unfortunately, this study did not evaluate
the effect of dovitinib on endothelial cells, and the con-
centration used was much higher than a pharmacologic-
ally relevant dose. In our study, dovitinib at 0.1 μmol/L
did not affect the viability or proliferation of HCC cell
lines in vitro. In contrast, it did inhibit endothelial cell
proliferation and motility at concentrations that also
inhibited VEGFR and FGFR signaling in these cells. Stud-
ies of HCC xenografts treated with pharmacologically
relevant concentrations of dovitinib showed more effect
on the inhibition of tumor angiogenesis in vivo than on
proliferation or apoptosis. Taken together, these data in-
dicate that dovitinib acts preferentially to target tumor
vasculature rather than cancer cells in the treatment
of HCC.
Some previous studies have reported that high expres-
sion of the angiogenic factors VEGF, basic FGF, and
platelet-derived growth factor receptor are detected in
patients with HCC, suggesting that VEGFR, FGFR, and
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Figure 6 Dovitinib inhibited proliferation and enhanced apoptosis in HCC xenograft tumors. A) Ki-67 staining showed the proliferation of
HCC cells was reduced in dovitinib-treated tumors. B) Cleaved PARP staining showed that apoptosis of HCC cells increased in dovitinib-treated
tumors. Scale bars, 300 μm. Black star, P < 0.05; double black star, P < 0.01.
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dovitinib-sensitive RTKs, only PDGFR-β was expressed
by SMMC7721 and MHCC-97H cells, where VEGFR-2
and FGFR-1 were highly expressed by endothelial cells.
Although high PDGFR-β expression has been correlated
with HCC progression [30], our in vitro studies showed
that dovitinib inhibition of PDGFR signaling was not suffi-
cient to inhibit the proliferation of HCC cells. Thus,
PDGFR signaling in HCC cells is likely through redundant
growth signaling pathways. In contrast, dovitinib inhibited
the phosphorylation of VEGFR-2 and FGFR-1 in endothe-
lial cells at similar concentrations, indicating the import-
ant role of VEGFR and FGFR signaling in the proliferation
of endothelial cells.
The endothelial cells recruited to the tumor tissue are
not only related to blood perfusion of the tumor, but they
are also believed to be involved in the cancer–stromal cell
interaction favoring tumor growth [31]. However, some
believe that normal endothelial cells may be the barrier to
hematogenous metastasis [32]. Blocking the adhesion of
tumor cells to endothelial cells prevents the implantation
of tumors cells in capillaries, thus inhibiting the migra-
tion of tumor cells in the circulation [33]. In ourprevious study, we found in HCC tissues that a distinct
pattern of endothelial structures, endothelium-coated
tumor clusters, was an independent predictor for survival
and recurrence in patients with HCC [6]. Endothelial
cells facilitate the efficiency of metastasis, irrespective of
the invasiveness of tumor cells [6]. In our study here, a
pharmacologically relevant concentration of dovitinib,
0.1 μmol/L, did not affect the migration or invasion of
HCC cell lines in vitro. In contrast, dovitinib did inhibit
endothelial cell migration and invasion and did so at
concentrations that also inhibited VEGFR and FGFR sig-
naling in these cells. Moreover, studies of orthotopic
HCC models treated with pharmacologically relevant
concentrations of dovitinib inhibited lung metastasis
in vivo. These findings suggest that the migration of
endothelial cells could be an important step in HCC me-
tastasis by providing an envelope that protects the tumor
cells in circulation [6].
Conclusion
In summary, we found that at pharmacologically rele-
vant concentrations, dovitinib targeted endothelial cells,
but not HCC cells, in inhibiting HCC growth and
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clarify the cellular target of dovitinib in the treatment of
HCC, which might be helpful for future development of
targeted therapy in HCC.
Additional files
Additional file 1: Figure S1. The markers of endothelial cell and
pericyte expressed homogeneously in tumor sample.
A) Immunohistochemical staining of CD31 in the tumor sample. B) CD34.
C) CD105. D) SMA.
Additional file 2: Figure S2. c-KIT and Flt-3 were undetectable in HCC
cell lines and endothelial cell lines.
Additional file 3: Figure S3. Effects of dovitinib on apoptosis and the
phosphorylation of Akt in HCC cell and endothelial cell lines. A) The
levels of cleaved PARP and cleaved caspase3 were also readily detected
in dose-dependence of dovitinib, but it do not show significant
difference between on HCC cell and endothelial cell lines. B) Dovitinib
does not reduced the basal phosphorylation levels of Akt in HCCcell
lines.
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